Immunnologist Prof Luke O’Neill, who is a co-founder and chief scientific officer at Inflamazone. Photograph: Nick Bradshaw

Irish specialty drug developer Inflazome has secured orphan drug designation for Inzomelid, a therapy that it is developing. Inflazome specialises i(...)